Omecamtiv mecarbil MR is a Small Molecule owned by Cytokinetics, and is involved in 21 clinical trials, which were completed.

Omecamtiv mecarbil (AMG 423, CK-1827452) is a cardiac myosin activator. The drug candidate weakens the heart muscle and inhibits their contraction, by activating a family of proteins called myosins. Cardiac muscle myosin activators work by a mechanism that directly stimulates the activity of the cardiac muscle myosin motor protein, without increasing the intracellular calcium concentration. They accelerate the rate-limiting step of the myosin enzymatic cycle and shift it in favor of the force-producing state. Rather than increasing the velocity of cardiac contraction, this mechanism instead lengthens the systolic ejection time, which results in increased cardiac muscle contractility and cardiac output in a potentially more oxygen-efficient manner.

The revenue for Omecamtiv mecarbil MR is expected to reach a total of $4.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Omecamtiv mecarbil MR NPV Report.

Omecamtiv mecarbil MR is originated and owned by Cytokinetics.

Omecamtiv mecarbil MR Overview

Omecamtiv mecarbil (CK-1827452, AMG-423) is under development for the treatment of heart failure and heart failure with reduced ejection fraction (systolic heart failure). It is administered by intravenous as form of a solution and oral route as a form of modified release tablet. Omecamtiv mecarbil is a small-molecule, direct activator of cardiac myosin. It is a modified release formulation and is a new molecular entity.

The drug candidate was also under development for the treatment of ischemic cardiomyopathy, left ventricular systolic dysfunction hospitalized for acute heart failure and angina.

Cytokinetics Overview

Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$70.4 million for the fiscal year ended December 2021 (FY2021), an increase of 26.2% over FY2020. The operating loss of the company was US$186.3 million in FY2021, compared to an operating loss of US$93.9 million in FY2020. The net loss of the company was US$215.3 million in FY2021, compared to a net loss of US$127.3 million in FY2020. The company reported revenues of US$2.5 million for the third quarter ended September 2022, a decrease of 97.2% over the previous quarter.

Quick View – Omecamtiv mecarbil MR

Report Segments
  • Innovator
Drug Name
  • Omecamtiv mecarbil MR
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.